|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Potosky AL, Saxman S, Wallace RB and Lynch
CF: Population variations in the initial treatment of
non-small-cell lung cancer. J Clin Oncol. 22:3261–3268. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramalingam S and Belani C: Systemic
chemotherapy for advanced non-small cell lung cancer: Recent
advances and future directions. Oncologist. 13 Suppl 1:S5–S13.
2008. View Article : Google Scholar
|
|
4
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Carcereny E, Gervais R, Gervais
R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, et al: Erlotinib versus standard chemotherapy as
first-line treatment for European patients with advanced EGFR
mutation-positive non-small-cell lung cancer (EURTAC): A
multicentre, open-label, randomised phase 3 trial. Lancet Oncol.
13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group, : Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M,
et al: Randomized phase III study of cisplatin plus irinotecan
versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shepherd FA, Pereira J Rodrigues, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:pp. 13306–13311. 2004;
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garassino MC, Martelli O, Broggini M,
Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F,
Moscetti L, et al: Erlotinib versus docetaxel as second-line
treatment of patients with advanced non-small-cell lung cancer and
wild-type EGFR tumours (TAILOR): A randomised controlled trial.
Lancet Oncol. 14:981–988. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Postmus PE, Brambilla E, Chansky K,
Crowley J, Goldstraw P, Patz EF Jr and Yokomise H: International
Association for the Study of Lung Cancer International Staging
Committee; Cancer Research and Biostatistics; Observers to the
Committee; Participating Institutions: The IASLC lung cancer
staging project: Proposals for revision of the M descriptors in the
forthcoming (seventh) edition of the TNM classification of lung
cancer. J Thorac Oncol. 2:686–693. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zubrod CG, Ipsen J, Frei E, Lc, Lipsett
Mb, Gehan E Lasagna and Escher Gc: Newer techniques and some
problems in cooperative group studies. Natl Cancer Inst Monogr.
3:277–292. 1960.PubMed/NCBI
|
|
20
|
Lee CK, Brown C, Gralla RJ, Hirsh V,
Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, et al:
Impact of EGFR inhibitor in non-small cell lung cancer on
progression-free and overall survival: A meta-analysis. J Natl
Cancer Inst. 105:595–605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cappuzzo F, Ciuleanu T, Stelmakh L,
Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W,
Melezínek I, et al: Erlotinib as maintenance treatment in advanced
non-small-cell lung cancer: A multicentre, randomised,
placebo-controlled phase 3 study. Lancet Oncol. 11:521–529. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Laurie SA and Goss GD: Role of epidermal
growth factor receptor inhibitors in epidermal growth factor
receptor wild-type non-small-cell lung cancer. J Clin Oncol.
31:1061–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shepherd FA, Dancey J, Ramlau R, Mattson
K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R,
et al: Prospective randomized trial of docetaxel versus best
supportive care in patients with non-small-cell lung cancer
previously treated with platinum-based chemotherapy. J Clin Oncol.
18:2095–2103. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fossella FV, DeVore R, Kerr RN, Crawford
J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, et al:
Randomized phase III trial of docetaxel versus vinorelbine or
ifosfamide in patients with advanced non-small-cell lung cancer
previously treated with platinum-containing chemotherapy regimens.
The TAX 320 non-small cell lung cancer study group. J Clin Oncol.
18:2354–2362. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kudoh S, Takeda K, Nakagawa K, Takada M,
Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, et al:
Phase III study of docetaxel compared with vinorelbine in elderly
patients with advanced non-small-cell lung cancer: Results of the
West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin
Oncol. 24:3657–3663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cho BC, Im CK, Park MS, Kim SK, Chang J,
Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, et al: Phase II study
of erlotinib in advanced non-small-cell lung cancer after failure
of gefitinib. J Clin Oncol. 25:2528–2533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Remon J, Morán T, Majem M, Reguart N,
Dalmau E, Márquez-Medina D and Lianes P: Acquired resistance to
epidermal growth factor receptor tyrosine kinase inhibitors in
EGFR-mutant non-small cell lung cancer: A new era begins. Cancer
Treat Rev. 40:93–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yun CH, Mengwasser KE, Toms AV, Woo MS,
Greulich H, Wong KK, Meyerson M and Eck MJ: The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for
ATP. Proc Natl Acad Sci USA. 105:pp. 2070–2075. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:pp. 20932–20937. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yano S, Wang W, Li Q, Matsumoto K,
Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka
Y, et al: Hepatocyte growth factor induces gefitinib resistance of
lung adenocarcinoma with epidermal growth factor
receptor-activating mutations. Cancer Res. 68:9479–9487. 2008.
View Article : Google Scholar : PubMed/NCBI
|
